Similarly, future studies should focus on 1) Evaluation of KRAS G12C inhibitors-anti-PD-1/PD-L1 inhibitor combination therapy in advanced NSCLC; 2) evaluation of adjuvant KRAS G12C inhibitor in surgically resected NSCLC with mKRAS G12C; and 3) assessment of the impact of KRAS G12C-comutations including TP53, STK11, and KEAP1, on prognosis. Here, KRAS is linked to non-small cell lung carcinoma.